Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 948573-26-0 | MDL No. : | MFCD08461903 |
Formula : | C5H10ClN3 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | QOVXVNPYUBGBDP-UHFFFAOYSA-N |
M.W : | 147.61 | Pubchem ID : | 44630890 |
Synonyms : |
|
Num. heavy atoms : | 9 |
Num. arom. heavy atoms : | 5 |
Fraction Csp3 : | 0.4 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 1.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 39.67 |
TPSA : | 43.84 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.74 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | 0.65 |
Log Po/w (WLOGP) : | 1.3 |
Log Po/w (MLOGP) : | 0.11 |
Log Po/w (SILICOS-IT) : | -0.05 |
Consensus Log Po/w : | 0.4 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -1.51 |
Solubility : | 4.56 mg/ml ; 0.0309 mol/l |
Class : | Very soluble |
Log S (Ali) : | -1.15 |
Solubility : | 10.5 mg/ml ; 0.0714 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -0.78 |
Solubility : | 24.4 mg/ml ; 0.166 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.47 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With 2-hydroxy-pyridine N-oxide; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃; for 20.0h; | Example 9; iV-(l-ethyl-ljHr-pyrazoI-4-yl)-2-[3-methoxy-5-(l,6-naphthyridin-4-yloxy)pyridin- 2-yl]acetamide; l-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.42 g) was added to a stirred mixture of 2-[3-methoxy-5-(l,6-naphthyridin-4-yloxy)pyridin-2-yl]acetic acid (0.225 g), 4-amino-l -ethyl- lT-pyrazole hydrochloride (0.14 g), diisopropylethylamine (0.5 ml), 2-hydroxypyridine iV-oxide (0.16 g) and DMF (2 ml). The resultant mixture was stirred at ambient temperature for 16 hours. A second portion (0.4 g) of 4-amino-l-ethyl- lH-pyrazole hydrochloride was added and the mixture was stirred at ambient temperature for 4 hours. The reaction mixture was purified by reversed-phase preparative HPLC on a Waters 'beta Basic Hypersil' reversed-phase preparative column (5 microns silica, 30 mm diameter, 250 mm length) using decreasingly polar mixtures of water (containing 0.2% ammonium carbonate) and acetonitrile as eluent. The material so obtained was triturated under a 19:1 mixture of diethyl ether and ethanol. The resultant product was isolated and dried under vacuum. There was thus obtained the title compound (0.095 g); 1H NMR Spectrum: (DMSOd6) 1.33 (t, 3H), 3.81 (s, 2H), 3.83 (s, 3H), 4.07 (q, 2H), 6.82 (d, IH), 7.42 (s, IH)5 7.62 (d, IH), 7.87 (s, IH), 7.94 (d, IH), 8.19 (d, IH), 8.84 (d, IH), 8.93 (d, IH), 9.74 (s, IH), 10.1 (s, IH); Mass Spectrum: M+H"1" 405. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With 2-hydroxy-pyridine N-oxide; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 17 - 25℃; for 16.0h; | The iV-(l-ethylpyrazol-4-yl)-2-(4-hydroxy-2-methoxyphenyl)acetamide used as starting material was prepared as follows :- l-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.845 g) was added to a stirred mixture of 2-(4-benzyloxy-2-methoxyphenyl)acetic acid (0.4 g), 1-ethyl- 4-aminopyrazole hydrochloride (0.239 g), 2-hydroxypyridine iV-oxide (0.327 g), diisopropylethylamine (1.03 ml) and DMF (5 ml) and the resultant mixture was stirred at ambient temperature for 16 hours. The solvent was evaporated and the residue was purified by column chromatography on silica using a gradient of 100:0 to 3:7 of methylene chloride and ethyl acetate as eluent. There was thus obtained iV-(l-ethylpyrazol-4-yl)-2-(4-benzyloxy-2-methoxyphenyl)acetamide (0.256 g); 1HNMR: (DMSOd6) 1.31 (t, 3H), 3.44 (s, 2H), 3.73 (s, 3H), 4.04 (q, 2H), 5.09 (s, 2H), 6.53 (m, IH), 6.62 (s, IH), 7.07 (d, IH), 7.33 (m, IH), 7.39 (m, 3H), 7.45 (m, 2H), 7.84 (s, IH), 9.89 (s, IH); Mass Spectrum: M+H+ 366. | |
With 2-hydroxy-pyridine N-oxide; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃; for 16.0h; | The iV-(l-ethylpyrazol-4-yl)-2-(4-hydroxy-2-methoxyphenyl)acetamide used as starting 0 material was prepared as follows :-; l-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.845 g) was added to a stirred mixture of 2-(4-benzyloxy-2-methoxyphenyl)acetic acid (0.4 g), 1-ethyl- 4-aminopyrazole hydrochloride (0.239 g), 2-hydroxypyridine iV-oxide (0.327 g), diisopropylethylamine (1.03 ml) and DMF (5 ml) and the resultant mixture was stirred at S ambient temperature for 16 hours. The solvent was evaporated and the residue was purified by column chromatography on silica using a gradient of 100:0 to 3:7 of methylene chloride and ethyl acetate as eluent. There was thus obtained N-(I -ethylpyrazol-4-yl)-2-(4-benzyloxy- 2-methoxyphenyl)acetamide (0.256 g); 1H NMR Spectrum: (DMSOd6) 1.31 (t, 3H), 3.44 (s, 2H)5 3.73 (s, 3H), 4.04 (q, 2H), 5.09 (s, 2H), 6.53 (m, IH), 6.62 (s, IH), 7.07 (d, IH), 7.33 (m, o IH), 7.39 (m, 3H), 7.45 (m, 2H), 7.84 (s, IH), 9.89 (s, IH); Mass Spectrum: M+H+ 366. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
51% | With palladium diacetate; 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl; sodium t-butanolate; In N,N-dimethyl-formamide; toluene; at 140℃; for 0.333333h;Microwave irradiation; | A mixture of 2-bromo-N-ieri-butyl-5-((2-(trimethylsilyl)ethoxy)methyl)-5H-pyrrolo[2,3- b]pyrazine-7-carboxamide (150 mg, 351 muiotaetaomicron), l-ethyl-lH-pyrazol-4-amine hydrochloride (51.8 mg, 526 muiotaetaomicron), BINAP (10.9 mg, 17.5 muiotaetaomicron), palladium (II) acetate (19.7 mg, 87.7 muiotaetaomicron) and sodium iert-butoxide (101 mg, 1.05 mmol, Eq: 3) in DMF (1 mL) and toluene (500 mu) was heated in a microwave at 140C for 20 min. The reaction mixture was diluted with water then extracted into ethyl acetate (3x). The combined organic extracts were washed with brine then dried over magnesium sulfate. Purification by chromatography (silica, 40-80 % ethyl acetate in hexanes) gave N-ieri-butyl-2-(l-ethyl-lH-pyrazol-4-ylamino)-5-((2-(trimethylsilyl)ethoxy) methyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide (82 mg, 179 muiotaetaomicron, 51 %) as a yellow gum. (EI/CI) m/z 458.4 [M + H]. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
30% | With hydrogenchloride; In 1,4-dioxane; isopropyl alcohol; at 140℃; for 2.0h;Microwave irradiation; | Synthesis of compound 1-97. To a solution of compound 115.5 (55 mg, 0.13 mmol, 1.00 equiv) in isopropanol (2 mL) was added 0.05 mL of hydrochloric acid (4 M in dioxane) followed by 1 -ethyl- lH-pyrazol-4-amine hydrochloride (23 mg, 0.16 mmol, 1.21 equiv) at room temperature. Reaction mixture was irradiated in microwave for 2 h at 140 C. Upon completion solvent was removed under vacuum and crude was purified via flash column chromatography. Additional purification was done via trituration with Cf^CVhexanes to give 19.6 mg (30%) of N4-(( lr,4r)-4-(4,4-difluoropiperidin- 1 -yl)cyclohexyl)-N2-( 1 -ethyl- 1 H-pyrazol-4-yl)-6,7-dihydro- 5H-cyclopenta[4,5]thieno[2,3-d]pyrimidine-2,4-diamine, 1-97 as a off-white solid. LCMS (ES, m/z): 502 [M+H]+, 1H NMR (400 MHz, CDC13): delta 7.86 (1H, s), 7.52 (1H, s), 6.56 (1H, s), 4.76 (1H, d), 4.17 (2H, q), 4.08-3.95 (1H, m), 2.93 (4H, brs), 2.76 (4H, brs), 2.62-2.45 (3H, m), 2.31 (2H, d), 2.20-1.92 (6H, m), 1.60-1.45 (5H, m), 1.35-1.18 (4H, m). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
16% | With potassium phosphate; XPhos; In tert-butyl alcohol; at 20℃;Inert atmosphere; | Into a 25 mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, were placed intermediate 55.1 (200 mg, 0.54 mmol, 1.00 equiv), potassium phosphate (346 mg, 1.63 mmol, 3.00 equiv), <strong>[948573-26-0]1-ethyl-1H-pyrazol-4-amine hydrochloride</strong> (120 mg, 0.82 mmol, 1.50 equiv), 2-methylpropan-2-ol (5 mL) and Xphos precatalyst (43 mg, 0.05 mmol, 0.10 equiv). The reaction was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum and the crude product was purified using preparative HPLC to furnish 38.1 mg (16%) of compound 1-56 as a pink solid. LCMS (ES, mlz): 444 [M+H] ?H NMR (400 MHz, CDC13): oe 7.553 (s, 1H), 7.903 (s, 1H), 5.1525.227 (m, 1H), 4.1004.184 (m,2H), 3.6743.739 (m, 4H), 2.6812.724 (d, 2H), 2.58O2.61O (t, 4H), 2.2882.325 (d, 3H),2.O652.1O3 (d, 2H), 1.4791.677 (m, 7 H). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
98% | In butan-1-ol; at 110℃; | Into a 50 mL round-bottom flask, was placed a solution of intermediate 7.7 (150 mg, 0.39 mmol, 1.00 equiv) in n-butanol (6 mL), and <strong>[948573-26-0]1-ethyl-1H-pyrazol-4-amine hydrochloride</strong> (87 mg, 0.78 mmol, 1.99 equiv). Reaction was stirred overnight at 110 C in an oil bath. Upon completion of the reaction resulting mixture was concentrated under vacuum, and crude purified using flash column chromatography to furnish 180 mg (98%) of compound 1-22 as a yellow solid. LCMS (ES, m/z): 457 [M+H] ?H NMR (400 MHz, DMSO) (5 9.03 (1H, s), 7.85 (1H, s), 7.46 (1H, s), 7.45 (br s, 1H), 4.07 (2H, q), 4.05-3.95 (1H, m), 3.58 (4H, br s), 2.97 (2H, q), 2.50 (4H, s), 2.25-2.16 (1H, m), 2.02-1.85 (4H, m), 1.52-1.42 (2H, m), 1.40-1.29 (8H, m). |
[ 1609395-52-9 ]
1-Ethyl-1H-pyrazol-4-amine dihydrochloride
Similarity: 1.00
[ 1185293-23-5 ]
1-Isopropyl-1H-pyrazol-4-amine hydrochloride
Similarity: 0.93
[ 1390654-83-7 ]
1-Propyl-1H-pyrazol-4-amine hydrochloride
Similarity: 0.93
[ 1185103-69-8 ]
1-Propyl-1H-pyrazol-4-amine dihydrochloride
Similarity: 0.93
[ 1609395-52-9 ]
1-Ethyl-1H-pyrazol-4-amine dihydrochloride
Similarity: 1.00
[ 1185293-23-5 ]
1-Isopropyl-1H-pyrazol-4-amine hydrochloride
Similarity: 0.93
[ 1390654-83-7 ]
1-Propyl-1H-pyrazol-4-amine hydrochloride
Similarity: 0.93
[ 1185103-69-8 ]
1-Propyl-1H-pyrazol-4-amine dihydrochloride
Similarity: 0.93